Improvement in residual paravalvular leakage after transcatheter aortic valve replacement with a self-expanding valve: ACURATE neo2 versus ACURATE neo

Figures

• 

  Fig. 1. Study workflow. This study included patients who underwent TTE at discharge and the 3-month follow-up after TAVR. TAVR transcatheter aortic valve replacement, TTE transthoracic echocardiography

• 

  Fig. 2. Comparison of mild grade or higher paravalvular leakage between the ACURATE neo2 and ACURATE neo groups at discharge and 3 months postoperatively. The ACURATE neo2 group shows a significant reduction in the incidence of mild grade or higher PVL at 3 months postoperatively compared to the ACURATE neo group. †P-values show the results of the McNemar test for paired data comparing the incidence of mild grade or higher PVL between discharge and 3 months for each valve type. The ACURATE neo2 group shows a significantly lower incidence of mild grade or higher PVL than the ACURATE neo group at 3 months. ‡P-values show the results of the chi-square test for unpaired data comparing the incidence of mild grade or higher PVL between the two valve types at each time. P-values in bold are statistically significant. PVL paravalvular leakage

• 

  Fig. 3. Multivariate analysis investigating the factors associated with paravalvular leakage improvement and mild grade or higher paravalvular leakage at 3 months postoperatively. a Use of ACURATE neo2 shows an independent association with PVL improvement, and CVAV significantly impedes PVL improvement. b Use of ACURATE neo2 significantly prevents mild grade or higher PVL at 3 months postoperatively. CVAV is independently associated with mild grade or higher PVL at 3 months postoperatively. P-values in bold are statistically significant. CI confidence interval, CVAV calcium volume of the aortic leaflets, LVOT left ventricular outflow tract, PVL paravalvular leakage, RR risk ratio

• 

  Fig. 4. Subgroup analysis for paravalvular leakage improvement and mild grade or higher paravalvular leakage at 3 months postoperatively. a Use of ACURATE neo2 was associated with PVL improvement. There were no significant interactions between THV type and anatomy of native aortic valve and between THV type and CVAV. b Use of ACURATE neo2 prevented mild grade or higher PVL at 3 months postoperatively. There were no significant interactions between THV type and anatomy of native aortic valve and between THV type and CVAV. AV aortic valve, CI confidence interval, CVAV calcium volume of the aortic leaflets, PVL paravalvular leakage, RR risk ratio, THV transcatheter heart valve